GeoVax is developing novel vaccines for infectious diseases and therapies for solid tumor cancers. Its lead clinical program is a next-generation COVID-19 vaccine for which GeoVax was awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b trial to evaluate the efficacy of GEO-CM04S1 versus an approved mRNA vaccine. GEO-CM04S1 is also currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned for 2025.